EyePoint Q3 net loss narrows to $12.6M; revenue up 52% on YUTIQ royalty recognition

EyePoint, Inc.

2023-Q3 EPS reported -$1.50 revenue$31,990,000

Total net revenue $15.2M (up 52% YoY) driven by $14.4M in royalties from YUTIQ sale.
Net loss $12.6M ($0.33/share) vs $18.4M ($0.49/share); cash $136.0M at quarter end.
EYP-1901 Phase 2 DAVIO 2 topline wet AMD data expected Dec 2023; PAVIA data Q2 2024.
No drug-related SAEs in ongoing EYP-1901 trials; Phase 2 VERONA in DME to start Q1 2024.
Leadership: George Elston promoted to EVP; Stuart Duty appointed to Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EyePoint, Inc. reported the third quarter ended September 30, 2023 results: revenue $15.2 million, net income $(12.6) million, EPS ($0.33) per share.

Period: the third quarter ended September 30, 2023
Revenue: $15.2 million
Net income: $(12.6) million
EPS: ($0.33) per share
Result: reported results

Exact text from the filing

For the third quarter ended September 30, 2023, total net revenue was $15.2 million compared to $10.0 million for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-057119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.